Two or three cycles of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma?

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer vol. 25 (2025), p. 1-13
Autor principal: Lin-Feng, Guo
Otros Autores: Yi-Feng, Yu, Zhen-Zhen Lu, Lin, Qin, San-Gang, Wu
Publicado:
Springer Nature B.V.
Materias:
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

MARC

LEADER 00000nab a2200000uu 4500
001 3236997184
003 UK-CbPIL
022 |a 1471-2407 
024 7 |a 10.1186/s12885-025-14699-4  |2 doi 
035 |a 3236997184 
045 2 |b d20250101  |b d20251231 
084 |a 58465  |2 nlm 
100 1 |a Lin-Feng, Guo 
245 1 |a Two or three cycles of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma? 
260 |b Springer Nature B.V.  |c 2025 
513 |a Journal Article 
520 3 |a PurposeTo investigate the optimal cycles of induction chemotherapy (IC) in patients with locoregionally advanced nasopharyngeal carcinoma (LANPC).MethodsWe included LANPC patients treated with two or three IC cycles from January 2015 to December 2021. The chi-square test, Kaplan-Meier method, propensity score matching (PSM), and Multivariate Cox regression analyses were used for statistical analysis.ResultsA total of 491 patients were included in this study, of whom 166 (33.8%) received two cycles and 325 (66.2%) received three cycles of IC. Patients with stage IVA disease (P < 0.001), advanced T stage (P = 0.011), and advanced N stage (P < 0.001) were more likely to receive three cycles of IC. Cox proportional hazards regression analyses showed that the number of IC cycles was not associated with better survival outcomes. Patients who received three cycles of IC had comparable LRFS (HR 0.992, 95% CI 0.525–1.875, P = 0.981), DMFS (HR 0.805, 95% CI 0.511–1.092, P = 0.351), PFS (HR 0.917, 95% CI 0.633–1.328, P = 0.645) and OS (HR 0.880, 95% CI 0.552–1.402, P = 0.590) compared to those with two cycles of IC. Similar results were found after PSM. No significant differences were found in the incidence of Grade 3–4 acute toxicities between the two and three-cycle groups. However, three cycles of IC significantly increased the incidence of Grade 1–2 leukopenia (P = 0.001), neutropenia (P = 0.015), anemia (P = 0.017), and vomiting (P = 0.024) compared to two cycles of IC.ConclusionsThe number of IC cycles (two or three) did not seem to affect the survival outcome of LANPC patients in this retrospective analysis. However, three cycles of IC were associated with a higher incidence of mild to moderate acute toxicities. Prospective studies in well-defined patient groups with a more uniform treatment program differing only in the number of IC cycles are warranted. 
610 4 |a Xiamen University 
651 4 |a China 
653 |a Epstein-Barr virus 
653 |a Neutropenia 
653 |a Medical prognosis 
653 |a Metastasis 
653 |a Toxicity 
653 |a Nasopharyngeal carcinoma 
653 |a Lymphatic system 
653 |a Oncology 
653 |a Survival 
653 |a Statistical analysis 
653 |a Chemotherapy 
653 |a Tumors 
653 |a Leukopenia 
653 |a Survival analysis 
700 1 |a Yi-Feng, Yu 
700 1 |a Zhen-Zhen Lu 
700 1 |a Lin, Qin 
700 1 |a San-Gang, Wu 
773 0 |t BMC Cancer  |g vol. 25 (2025), p. 1-13 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3236997184/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3236997184/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3236997184/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch